Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 5
Submit an article Journal homepage
383
Views
53
CrossRef citations to date
0
Altmetric
Reviews

Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis

Vaia Pliaka University of Thessaly, School of Health Sciences, Department of Biochemistry and Biotechnology, Microbiology–Virology Laboratory, Larissa, Greece. [email protected]
,
Zaharoula Kyriakopoulou University of Thessaly, School of Health Sciences, Department of Biochemistry and Biotechnology, Microbiology–Virology Laboratory, Larissa, Greece
&
Panayotis Markoulatos University of Thessaly, School of Health Sciences, Department of Biochemistry and Biotechnology, Microbiology–Virology Laboratory, Larissa, Greece
Pages 609-628 | Published online: 09 Jan 2014

References

  • Racaniello VR. Picornaviridae: the viruses and their replication. In: Fields Virology (5th Edition, Volume I). Knipe DM, Howley PM (Eds.) Lippincott Williams & Wilkins, PA, USA, 765 (2007).
  • Brown B, Oberste MS, Maher K, Pallansch MA. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J. Virol. 77(16), 8973–8984 (2003).
  • Nathanson N. The pathogenesis of poliomyelitis: what we don’t know. Adv. Virus Res. 71, 1–50 (2008).
  • Sartwell PE. The incubation period of poliomyelitis. Am. J. Public Health Nations. Health 42(11), 1403–1408 (1952).
  • Melnick JL. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Virology (2nd Edition). Fields B, Knipe D (Eds.), Raven Press, NY, USA, 549 (1990).
  • Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175(Suppl. 1), S176–S182 (1997).
  • Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J. Infect. Dis. 163(1), 1–6 (1991).
  • Jacques J, Moret H, Minette D et al. Epidemiological, molecular, and clinical features of enterovirus respiratory infections in French children between 1999 and 2005. J. Clin. Microbiol. 46(1), 206–213 (2008).
  • Oberste MS, Maher K, Schnurr D et al. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J. Gen. Virol. 85(Pt 9), 2577–2584 (2004).
  • Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am. J. Epidemiol. 150(10), 1001–1021 (1999).
  • Bodian D. Immunologic classification of poliomyelitis viruses. I. A cooperative program for the typing of one hundred strains. Am. J. Hyg. 54(2), 191–204 (1951).
  • Minor PD. Antigenic structure of picornaviruses. Curr. Top. Microbiol. Immunol. 161, 121–154 (1990).
  • Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229(4720), 1358–1365 (1985).
  • Wimmer E, Hellen CU, Cao X. Genetics of poliovirus. Annu. Rev. Genet. 27, 353–436 (1993).
  • Paul AV, Peters J, Mugavero J, Yin J, van Boom JH, Wimmer E. Biochemical and genetic studies of the VPg uridylylation reaction catalyzed by the RNA polymerase of poliovirus. J. Virol. 77(2), 891–904 (2003).
  • Domingo E, Escarmís C, Sevilla N et al. Basic concepts in RNA virus evolution. FASEB J. 10(8), 859–864 (1996).
  • Friedberg EC, Walker GC, Siede W. DNA Repair and Mutagenesis. ASM Press, DC, USA (1995).
  • Gmyl AP, Belousov EV, Maslova SV, Khitrina EV, Chetverin AB, Agol VI. Nonreplicative RNA recombination in poliovirus. J. Virol. 73(11), 8958–8965 (1999).
  • Kirkegaard K, Baltimore D. The mechanism of RNA recombination in poliovirus. Cell 47(3), 433–443 (1986).
  • Pierangeli A, Bucci M, Forzan M, Pagnotti P, Equestre M, Pérez Bercoff R. ‘Primer alignment-and-extension’: a novel mechanism of viral RNA recombination responsible for the rescue of inactivated poliovirus cDNA clones. J. Gen. Virol. 80(Pt 8), 1889–1897 (1999).
  • White KA, Morris TJ. RNA determinants of junction site selection in RNA virus recombinants and defective interfering RNAs. RNA 1(10), 1029–1040 (1995).
  • Freistadt MS, Vaccaro JA, Eberle KE. Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase. Virol. J. 4, 44 (2007).
  • Lai MM. RNA recombination in animal and plant viruses. Microbiol. Rev. 56(1), 61–79 (1992).
  • Worobey M, Holmes EC. Evolutionary aspects of recombination in RNA viruses. J. Gen. Virol. 80(Pt 10), 2535–2543 (1999).
  • Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health Nations. Health 44(5), 563–570 (1954).
  • Robertson SE, Traverso HP, Drucker JA et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1(8591), 897–899 (1988).
  • Offit PA. The Cutter Incident: How America’s First Polio Vaccine Led to the Growing Vaccine Crisis. Yale University Press, CT, USA (2005).
  • Melnick JL, Brennan JC. Monkey neurovirulence of attenuated poliovirus vaccines being used in field trials. In: Live Polio Virus Vaccines. PAHO, DC, USA, 65–101 (1959).
  • Chumakov MP. The effect of mass peroral immunisation by live vaccines from Sabin strains on the epidemiological process of poliomyelitis. J. Hyg. Epidemiol. Microbiol. Immunol. 4, 287–288 (1960).
  • Sabin AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J. Am. Med. Assoc. 164(11), 1216–1223 (1957).
  • Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151(3), 420–436 (1985).
  • Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1, 115–118 (1973).
  • Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type1 poliovirus Sabin vaccine. J. Virol. 69(8), 4972–4978 (1995).
  • Georgescu MM, Tardy-Panit M, Guillot S, Crainic R, Delpeyroux F. Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus. J. Virol. 69(9), 5278–5286 (1995).
  • Macadam AJ, Arnold C, Howlett J et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type3 strain of poliovirus in vaccinees. Virology 172(2), 408–414 (1989).
  • Macadam AJ, Pollard SR, Ferguson G et al. The 5′ noncoding region of the type2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181(2), 451–458 (1991).
  • Bodian D. Discussion. Infection and immunity in poliomyelitis. In: Papers and Discussions Presented at The Third International Poliomyelitis Conference. JB Lippincott, PA, USA, 196–201 (1954).
  • Plotkin SA, Koprowski H, Stokes J Jr. Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics 23(6), 1041–1062 (1959).
  • Sutter R, Cochi S, Melnick JL. Live attenuated poliovirus vaccine. In: Vaccines (3rd Edition). Plotkin SA, Orenstein WA (Eds.), WB Saunders, PA, USA, 364–408 (1999).
  • Fine PE. Polio: measuring the protection that matters most. J. Infect. Dis. 200(5), 673–675 (2009).
  • Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine using countries. Wkly. Epidemiol. Rec. 78(28), 241–250 (2003).
  • Fox JP. Modes of action of poliovirus vaccines and relation to resulting immunity. Rev. Infect. Dis. 6(Suppl. 2), S352–S355 (1984).
  • Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Rev. Infect. Dis. 6(Suppl. 2), S361–S368 (1984).
  • Sabin AB. Recent studies and field tests with a live attenuated poliovirus vaccine. In: First International Conference on Live Poliovirus Vaccines, Papers Presented and Discussions Held. Pan American Sanitary Bureau, DC, USA, 44, 14–33 (1959).
  • Horstmann DM, Niederman JC, Paul JR. Attenuated type1 poliovirus vaccine; its capacity to infect and to spread from vaccinees within an institutional population. J. Am. Med. Assoc. 170(1), 1–8 (1959).
  • Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J. Infect. Dis. 182(1), 1–5 (2000).
  • Svennerholm AM, Hanson LA, Holmgren J et al. Antibody responses to live and killed poliovirus vaccines in the milk of Pakistani and Swedish women. J. Infect. Dis. 143(5), 707–711 (1981).
  • Zaman S, Carlsson B, Jalil F et al. Comparison of serum and salivary antibodies in children vaccinated with oral live or parenteral inactivated poliovirus vaccines of different antigen concentrations. Acta Paediatr. Scand. 80(12), 1166–1173 (1991).
  • Carlsson B, Zaman S, Mellander L, Jalil F, Hanson LA. Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination. J. Infect. Dis. 152(6), 1238–1244 (1985).
  • Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162(6), 1291–1297 (1990).
  • WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. Bull. World Health Organ. 74(3), 253–268 (1996).
  • Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N. Engl. J. Med. 356(15), 1536–1544 (2007).
  • Laassri M, Lottenbach K, Belshe R et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J. Infect. Dis. 192(12), 2092–2098 (2005).
  • Dick GW, Dane DS, McAlister J, Briggs M, Nelson R, Field CM. Vaccination against poliomyelitis with live virus vaccines. 7. Effect of previous Salk vaccination on virus excretion. Br. Med. J. 2(5247), 266–269 (1961).
  • Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type1 poliomyelitis epidemic. Am. J. Hyg. 76, 173–195 (1962).
  • Schonberger LB, Kaplan J, Kim-Farley R, Moore M, Eddins DL, Hatch M. Control of paralytic poliomyelitis in the United States. Rev. Infect. Dis. 6(Suppl. 2), S424–S426 (1984).
  • Lapinleimu K. Elimination of poliomyelitis in Finland. Rev. Infect. Dis. 6(Suppl. 2), S457–S460 (1984).
  • WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine – results of a ten-year enquiry. Bull. World Health Organ. 60(2), 231–242 (1982).
  • Salk D, van Wezel AL, Salk J. Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 2(8415), 1317–1321 (1984).
  • Rümke HC, Oostvogel PM, Van Steenis G, Van Loon AM. Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol. Infect. 115(2), 289–298 (1995).
  • Böttiger M, Fagraeus A. Polio vaccination in Sweden. Rev. Infect. Dis. 2, 274–276 (1980).
  • Lapinleimu K. Elimination of poliomyelitis in Finland. Rev. Infect. Dis. 6(Suppl. 2), S457–S460 (1984).
  • Plotkin SA, Vidor E. Poliovirus vaccine—inactivated. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds.), WB Saunders Company, PA, USA, 625–649 (2004).
  • Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 14(8), 735–746 (1996).
  • Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 26(39), 4978–4983 (2008).
  • van Wezel AL, van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev. Biol. Stand. 41, 159–168 (1978).
  • Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr. Infect. Dis. J. 16(3), 312–322 (1997).
  • Rennels MB. Need for polio boosters after age two years. Vaccine 27(2), 179–180 (2009).
  • Hull HF, Ward NA, Hull BP, Milstien JB, de Quadros C. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343(8909), 1331–1337 (1994).
  • Sabin AB, Michaels RH, Spigland I, Pelon W, Rhim JS, Wehr RE. Community-wide use of oral poliovirus vaccine. Efectiveness of the Cincinnati program. Am. J. Dis. Child. 101, 546–567 (1961).
  • World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J. Infect. Dis. 171(5), 1097–1106 (1995).
  • de Quadros CA, Andrus JK, Olivé JM, Carrasco P. Strategies for poliomyelitis eradication in developing countries. Public Health Rev. 21(1–2), 65–81 (1993–1994).
  • Kim-Farley RJ, Rutherford G, Lichfield P et al. Outbreak of paralytic poliomyelitis, Taiwan. Lancet 2(8415), 1322–1324 (1984).
  • Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds.). Saunders Elsevier, PA, USA, 631–685 (2008).
  • Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59, 587–635 (2005).
  • CDC. Progress toward interruption of wild poliovirus transmission–worldwide, 2008. Morb. Mort. Wkly. Rep. 58(12), 308–312 (2009).
  • Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27(20), 2649–2652 (2009).
  • Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am. J. Epidemiol. 162(4), 358–372 (2005).
  • Thompson KM, Tebbens RJ, Pallansch MA et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am. J. Public Health 98(7), 1322–1330 (2008).
  • Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 297(5583), 1016–1018 (2002).
  • Peart AF, Rhodes AJ. An outbreak of poliomyelitis in Canadian Eskimos in wintertime. Can. J. Public Health. 40(10), 405–419 (1949).
  • Rhodes AJ, Chapman M. Some observations on interference between neurotropic viruses. Can. J. Res. 27(6 Sect. E), 341–348 (1949).
  • CDC. Progress toward global eradication of poliomyelitis, 2001. Morb. Mortal. Wkly Rep. 51(12), 253–256 (2002).
  • Polio Global Eradication Initiative: annual report 2012. WHO, Geneva, Switzerland (2011).
  • CDC. Progress toward global eradication of poliomyelitis, 1999. Morb. Mortal. Wkly Rep. 49, 349–354 (2002).
  • Wassilak S, Oblapenko G, Dittmann S. Progress in Europe towards the goal of poliomyelitis eradication. Euro Surveill. 2(5), 39–41 (1997).
  • Arita I, Nakane M. Road map for polio eradication–establishing the link with Millennium Development Goal no. 4 for child survival. Jpn. J. Infect. Dis. 61(3), 169–174 (2008).
  • Grassly NC, Fraser C, Wenger J et al. New strategies for the elimination of polio from India. Science 314(5802), 1150–1153 (2006).
  • Grassly NC, Wenger J, Durrani S et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case–control study. Lancet 369(9570), 1356–1362 (2007).
  • el-Sayed N, el-Gamal Y, Abbassy AA et al. Monovalent type1 oral poliovirus vaccine in newborns. N. Engl. J. Med. 359(16), 1655–1665 (2008).
  • Graf H. Manufacturing and supply of monovalent oral polio vaccines. Biologicals 34(2), 141–144 (2006).
  • WHO. Advisory Committee on Poliomyelitis Eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Wkly Epidemiol. Rec. 84(29), 289–290 (2009).
  • Oostvogel PM, van Wijngaarden JK, van der Avoort HG et al. Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992–93. Lancet 344(8923), 665–670 (1994).
  • Ciofi Degli Atti M, Prevots R, Sallabanda A et al. Polio outbreak in Albania, 1996. Euro Surveill. 2(5), 37–39 (1997).
  • Kyriakopoulou Z, Kottaridi C, Dedepsidis E, Bolanaki E, Levidiotou-Stefanou S, Markoulatos P. Molecular characterization of wild-type polioviruses isolated in Greece during the 1996 outbreak in Albania. J. Clin. Microbiol. 44(3), 1150–1152 (2006).
  • CDC. Resurgence of wild poliovirus type 1 transmission and consequences of importation–21 countries, 2002–2005. Morb. Mort. Wkly Rep. 55(6), 145–150 (2006).
  • CDC. Wild poliovirus type 1 and type 3 importations–15 countries, Africa, 2008–2009. Morb. Mort. Wkly Rep. 58(14), 357–362 (2009).
  • Yakovenko ML, Cherkasova EA, Rezapkin GV et al. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J. Virol. 80(6), 2641–2653 (2006).
  • Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T. Prevalence of vaccine-derived polioviruses in the environment. J. Gen. Virol. 83(Pt 5), 1107–1111 (2002).
  • Adu F, Iber J, Bukbuk D et al. Isolation of recombinant type2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res. 127(1), 17–25 (2007).
  • Crainic R, Couillin P, Blondel B, Cabau N, Boué A, Horodniceanu F. Natural variation of poliovirus neutralization epitopes. Infect. Immun. 41(3), 1217–1225 (1983).
  • Minor PD, John A, Ferguson M, Icenogle JP. Antigenic and molecular evolution of the vaccine strain of type3 poliovirus during the period of excretion by a primary vaccinee. J. Gen. Virol. 67(Pt 4), 693–706 (1986).
  • Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J. Virol. 74(16), 7381–7390 (2000).
  • Yang CF, Chen HY, Jorba J et al. Intratypic recombination among lineages of type1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79(20), 12623–12634 (2005).
  • Odoom JK, Yunus Z, Dunn G, Minor PD, Martín J. Changes in population dynamics during long-term evolution of Sabin type1 poliovirus in an immunodeficient patient. J. Virol. 82(18), 9179–9190 (2008).
  • Cuervo NS, Guillot S, Romanenkova N et al. Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccinees. J. Virol. 75(13), 5740–5751 (2001).
  • Savolainen-Kopra C, Samoilovich E, Kahelin H, Hiekka AK, Hovi T, Roivainen M. Comparison of poliovirus recombinants: accumulation of point mutations provides further advantages. J. Gen. Virol. 90(Pt 8), 1859–1868 (2009).
  • Blomqvist S, Bruu AL, Stenvik M, Hovi T. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1. J. Gen. Virol. 84(Pt 3), 573–580 (2003).
  • Martín J, Samoilovich E, Dunn G et al. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J. Virol. 76(21), 10921–10928 (2002).
  • Georgescu MM, Delpeyroux F, Tardy-Panit M et al. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 68(12), 8089–8101 (1994).
  • Christodoulou C, Colbere-Garapin F, Macadam A et al. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J. Virol. 64(10), 4922–4929 (1990).
  • Georgescu MM, Balanant J, Macadam A et al. Evolution of the Sabin type1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 71(10), 7758–7768 (1997).
  • Martín J, Odoom K, Tuite G et al. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78(24), 13839–13847 (2004).
  • Gutiérrez AL, Denova-Ocampo M, Racaniello VR, del Angel RM. Attenuating mutations in the poliovirus 5′ untranslated region alter its interaction with polypyrimidine tract-binding protein. J. Virol. 71(5), 3826–3833 (1997).
  • Cello J, Toyoda H, Dejesus N, Dobrikova EY, Gromeier M, Wimmer E. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. J. Med. Virol. 80(2), 352–359 (2008).
  • Malnou CE, Werner A, Borman AM, Westhof E, Kean KM. Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild-type poliovirus type1 context. J. Biol. Chem. 279(11), 10261–10269 (2004).
  • De Jesus N, Franco D, Paul A, Wimmer E, Cello J. Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J. Virol. 79(22), 14235–14243 (2005).
  • Pliaka V, Filliponi ME, Kyriakopoulou Z et al. Retrospective molecular and phenotypic analysis of poliovirus vaccine strains isolated in Greece. Clin. Microbiol. Infect. 17(10), 1554–1562 (2011).
  • Pliaka V, Dedepsidis E, Kyriakopoulou Z et al. Growth kinetic analysis of bi-recombinant poliovirus vaccine strains. Virus Genes 40(2), 200–211 (2010).
  • Pliaka V, Kyriakopoulou Z, Tsakogiannis D et al. Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains. Eur. J. Clin. Microbiol. Infect. Dis. 29(12), 1513–1523 (2010).
  • Horie H, Yoshida H, Matsuura K et al. Isolation of vaccine-derived type1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J. Med. Virol. 68(3), 445–451 (2002).
  • Pliaka V, Dedepsidis E, Kyriakopoulou Z, Papadopoulou I, Levidiotou S, Markoulatos P. Use of mutational pattern in 5′-NCR and VP1 regions of polioviruses for molecular diagnosis. Mol. Cell. Probes 21(4), 267–275 (2007).
  • John TJ. Vaccine-associated paralytic polio in India. Bull. World Health Organ. 80(11), 917 (2002).
  • Strebel PM, Sutter RW, Cochi SL et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14(2), 568–579 (1992).
  • Buttinelli G, Donati V, Fiore S et al. Nucleotide variation in Sabin type2 poliovirus from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 84(Pt 5), 1215–1221 (2003).
  • Cherkasova EA, Yakovenko ML, Rezapkin GV et al. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J. Virol. 79(2), 1062–1070 (2005).
  • Manor Y, Handsher R, Halmut T et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J. Clin. Microbiol. 37(6), 1670–1675 (1999).
  • Kohler KA, Banerjee K, Gary Hlady W, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull. World Health Organ. 80(3), 210–216 (2002).
  • Otelea D, Guillot S, Furione M et al. Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Dev. Biol. Stand. 78, 33–38 (1993).
  • Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type3. J. Virol. 78(20), 11097–11107 (2004).
  • Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63(2), 353–362 (1990).
  • Minor PD, Dunn G. The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. J. Gen. Virol. 69 (Pt 5), 1091–1096 (1988).
  • Macadam AJ, Pollard SR, Ferguson G et al. Genetic basis of attenuation of the Sabin type2 vaccine strain of poliovirus in primates. Virology 192(1), 18–26 (1993).
  • Minor PD. The molecular biology of poliovaccines. J. Gen. Virol. 73 (Pt 12), 3065–3077 (1992).
  • Friedrich F. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virol. 40(3), 157–170 (1996).
  • Friedrich F, Da-Silva EF, Schatzmayr HG. type2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil. Acta Virol. 40(1), 27–33 (1996).
  • King AM. Preferred sites of recombination in poliovirus RNA: an analysis of 40 intertypic cross-over sequences. Nucleic Acids Res. 16(24), 11705–11723 (1988).
  • Cherkasova EA, Korotkova EA, Yakovenko ML et al. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J. Virol. 76(13), 6791–6799 (2002).
  • Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196(1), 199–208 (1993).
  • Lipskaya GY, Muzychenko AR, Kutitova OK et al. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J. Med. Virol. 35(4), 290–296 (1991).
  • Blomqvist S, Savolainen C, Laine P et al. Characterization of a highly evolved vaccine-derived poliovirus type3 isolated from sewage in Estonia. J. Virol. 78(9), 4876–4883 (2004).
  • Mueller JE, Bessaud M, Huang QS et al. Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina. Appl. Environ. Microbiol. 75(5), 1395–1401 (2009).
  • Zurbriggen S, Tobler K, Abril C et al. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl. Environ. Microbiol. 74(18), 5608–5614 (2008).
  • Combiescu M, Guillot S, Persu A et al. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania. Arch. Virol. 152(4), 727–738 (2007).
  • Driesel G, Diedrich S, Kunkel U, Schreier E. Vaccine-associated cases of poliomyelitis over a 30 year period in East Germany. Eur. J. Epidemiol. 11(6), 647–654 (1995).
  • Kew O, Morris-Glasgow V, Landaverde M et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type1 vaccine-derived poliovirus. Science 296(5566), 356–359 (2002).
  • Karakasiliotis I, Markoulatos P, Katsorchis T. Site analysis of recombinant and mutant poliovirus isolates of Sabin origin from patients and from vaccinees. Mol. Cell. Probes 18(2), 103–109 (2004).
  • Dedepsidis E, Pliaka V, Kyriakopoulou Z et al. Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant. FEMS Immunol. Med. Microbiol. 52(3), 343–351 (2008).
  • Blomqvist S, Savolainen-Kopra C, Paananen A et al. Recurrent isolation of poliovirus 3 strains with chimeric capsid protein Vp1 suggests a recombination hot-spot site in Vp1. Virus Res. 151(2), 246–251 (2010).
  • Karakasiliotis I, Paximadi E, Markoulatos P. Evolution of a rare vaccine-derived multirecombinant poliovirus. J. Gen. Virol. 86(Pt 11), 3137–3142 (2005).
  • Paximadi E, Karakasiliotis I, Mamuris Z, Stathopoulos C, Krikelis V, Markoulatos P. Genomic analysis of recombinant sabin clinical isolates. Virus Genes 32(2), 203–210 (2006).
  • Boot HJ, Schepp RM, van Nunen FJ, Kimman TG. Rapid RT-PCR amplification of full-length poliovirus genomes allows rapid discrimination between wild-type and recombinant vaccine-derived polioviruses. J. Virol. Methods 116(1), 35–43 (2004).
  • Liu HM, Zheng DP, Zhang LB, Oberste MS, Kew OM, Pallansch MA. Serial recombination during circulation of type1 wild-vaccine recombinant polioviruses in China. J. Virol. 77(20), 10994–11005 (2003).
  • Dedepsidis E, Kyriakopoulou Z, Pliaka V, Markoulatos P. Correlation between recombination junctions and RNA secondary structure elements in poliovirus Sabin strains. Virus Genes 41(2), 181–191 (2010).
  • Kilpatrick DR, Ching K, Iber J et al. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J. Clin. Microbiol. 42(9), 4313–4315 (2004).
  • Pliaka V, Dedepsidis E, Kyriakopoulou Z et al. A new RT-PCR assay for the identification of the predominant recombination types in 2C and 3D genomic regions of vaccine-derived poliovirus strains. Mol. Cell. Probes 24(3), 115–123 (2010).
  • WHO. Expanding contributions of the Global Laboratory Network for Poliomyelitis Eradication, 2000–2001. Wkly Epidemiol. Rec. 77, 133 (2002).
  • Manual for the virological investigation of polio (WHO/EPI/GEN/97.01). WHO, Geneva, Switzerland (2004).
  • Agol VI. Vaccine-derived polioviruses. Biologicals 34(2), 103–108 (2006).
  • WHO. Global update on vaccine-derived polioviruses, January 2006–August 2007. Wkly Epidemiol. Rec. 82, 337–344 (2007).
  • WHO. Vaccine-derived polioviruses detected worldwide, July 2009−March 2011. Wkly Epidemiol. Rec. 86, 277–288 (2011).
  • Update on vaccine-derived polioviruses – worldwide, January 2008–June 2009. MMWR Morb. Mortal. Wkly Rep. 58, 1002–1006 (2009).
  • Kew OM, Wright PF, Agol VI et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull. World Health Organ. 82(1), 16–23 (2004).
  • Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS ONE 3(10), e3433 (2008).
  • Laboratory surveillance for wild and vaccine-derived polioviruses – worldwide, January 2007 June 2008. MMWR Morb. Mortal. Wkly Rep. 57, 967–970 (2008).
  • Shimizu H, Thorley B, Paladin FJ et al. Circulation of type1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 78(24), 13512–13521 (2004).
  • Liang X, Zhang Y, Xu W et al. An outbreak of poliomyelitis caused by type1 vaccine-derived poliovirus in China. J. Infect. Dis. 194(5), 545–551 (2006).
  • Estívariz CF, Watkins MA, Handoko D et al. A large vaccine-derived poliovirus outbreak on Madura Island – Indonesia, 2005. J. Infect. Dis. 197(3), 347–354 (2008).
  • Update on vaccine-derived polioviruses. MMWR Morb. Mortal. Wkly Rep. 55, 1093–1097 (2006).
  • Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerging Infect. Dis. 9(7), 885–887 (2003).
  • Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am. J. Epidemiol. 110(6), 672–692 (1979).
  • Yang CF, Naguib T, Yang SJ et al. Circulation of endemic type2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J. Virol. 77(15), 8366–8377 (2003).
  • Thorley B, Paladin F, Shimizu H. Presented at: XIIth International Congress of Virology. Paris, France, 27 July–1 August 2002.
  • Riquet FB, Blanchard C, Jegouic S et al. Impact of exogenous sequences on the characteristics of an epidemic type2 recombinant vaccine-derived poliovirus. J. Virol. 82(17), 8927–8932 (2008).
  • Martín J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 34(2), 117–122 (2006).
  • Halsey NA, Pinto J, Espinosa-Rosales F et al.; Polio Project Team. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull. World Health Organ. 82(1), 3–8 (2004).
  • Khetsuriani N, Prevots DR, Quick L et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 188(12), 1845–1852 (2003).
  • MacLennan C, Dunn G, Huissoon AP et al. Failure to clear persistentvaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363(9420), 1509–1513 (2004).
  • Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev. Biol. (Basel) 105, 75–80 (2001).
  • Avellón A, Cabrerizo M, de Miguel T et al. Paralysis case and contact spread of recombinant vaccine-derived poliovirus, Spain. Emerging Infect. Dis. 14(11), 1807–1809 (2008).
  • Martín J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the Sabin strain of type3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74(7), 3001–3010 (2000).
  • Sutter R, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect. Med. 11, 426–438 (1994).
  • Kew OM, Sutter RW, Nottay BK et al. Prolonged replication of a type1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36(10), 2893–2899 (1998).
  • Cernáková B, Sobotová Z, Rovný I, Bláhova S, Roivainen M, Hovi T. Isolation of vaccine-derived polioviruses in the Slovak Republic. Eur. J. Clin. Microbiol. Infect. Dis. 24(6), 438–439 (2005).
  • Shulman LM, Manor Y, Handsher R et al. Molecular and antigenic characterization of a highly evolved derivative of the type2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 38(10), 3729–3734 (2000).
  • Dedepsidis E, Kyriakopoulou Z, Pliaka V et al. Retrospective characterization of a vaccine-derived poliovirus type1 isolate from sewage in Greece. Appl. Environ. Microbiol. 73(21), 6697–6704 (2007).
  • Heymann DL, Sutter RW, Aylward RB. A global call for new polio vaccines. Nature 434(7034), 699–700 (2005).
  • Aylward RB, Sutter RW, Heymann DL. Policy. OPV cessation–the final step to a ‘polio-free’ world. Science 310(5748), 625–626 (2005).
  • Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nat. Rev. Microbiol. 5(12), 952–958 (2007).
  • Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev. Med. Virol. 13(5), 277–291 (2003).
  • Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol. Rec. 81(15), 137–144 (2006).
  • Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28(6), 573–579 (2010).
  • Wyman O. Global post-eradication IPV supply and demand assessment: integrated findings. Bill and Melinda Gates Foundation, WA, USA (2009).
  • Dayan GH, Thorley M, Yamamura Y et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J. Infect. Dis. 195(1), 12–20 (2007).
  • Griffiths UK, Botham L, Schoub BD. The cost–effectiveness of alternative polio immunization policies in South Africa. Vaccine 24(29–30), 5670–5678 (2006).
  • Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro Surveill. 12(6), E7–E8 (2007).
  • Pliaka V, Ruether IG, Kyriakopoulou Z et al. A seroprevalence study of poliovirus antibody against a collection of recombinant and non-recombinant poliovirus vaccine strains in the population of southern Greece. Clin. Microbiol. Infect. 16(11), 1672–1675 (2010).
  • Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin. Microbiol. Infect. 11(1), 68–71 (2005).
  • Mastroeni I, Patti AM, Fabrizi A et al. Immunity status against poliomyelitis in persons 13–14 years old living in Rome. Vaccine 15(6–7), 747–750 (1997).
  • White PM, Green J. Prevalence of antibody to poliovirus in England and Wales 1984–6. Br. Med. J. (Clin. Res. Ed.) 293(6555), 1153–1155 (1986).
  • Frantzidou-Adamopoulou F. Poliomyelitis cases in northern Greece during 1976–1990. Eur. J. Epidemiol. 8(1), 112–113 (1992).
  • Yakovenko ML, Korotkova EA, Ivanova OE et al. Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J. Virol. 83(7), 3402–3406 (2009).
  • Rakoto-Andrianarivelo M, Guillot S, Iber J et al. Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar. PLoS Pathog. 3(12), e191 (2007).
  • Romanenkova NI, Guillot S, Rozaeva NR, Crainic R, Bichurina MA, Delpeyroux F. Use of a multiple restriction fragment length polymorphism method for detecting vaccine-derived polioviruses in clinical samples. J. Clin. Microbiol. 44(11), 4077–4084 (2006).
  • WHO. Informal consultation of the Global Polio Laboratory Network. Wkly Epidemiol. Rec. 83, 261–268 (2008).
  • Cherkasova E, Laassri M, Chizhikov V et al. Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc. Natl Acad. Sci. USA. 100(16), 9398–9403 (2003).
  • Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 25(41), 7041–7046 (2007).
  • WHO. Improving IPV. The Polio Pipeline 1, 2–3 (2008).
  • WHO. Update on improving IPV. The Polio Pipeline 3, 3 (2009).
  • WHO. Polio Research Committee outcomes. The Polio Pipeline 3, 1 (2009).
  • Kreeftenberg H, van der Velden T, Kersten G, van der Heuvel N, de Bruijn M. Technology transfer of Sabin IPV to new developing country markets. Biologicals 34(2), 155–158 (2006).
  • Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc. Natl Acad. Sci. USA 93(6), 2370–2375 (1996).
  • Macadam AJ, Ferguson G, Stone DM et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 80(17), 8653–8663 (2006).
  • Agol VI, Pilipenko EV, Slobodskaya OR. Modification of translational control elements as a new approach to design of attenuated picornavirus strains. J. Biotechnol. 44(1–3), 119–128 (1996).
  • Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14(2), 154–161 (2008).
  • Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem. 280(27), 25706–25716 (2005).
  • Burns CC, Shaw J, Campagnoli R et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J. Virol. 80(7), 3259–3272 (2006).
  • Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80(19), 9687–9696 (2006).
  • Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4(3), 239–248 (2008).
  • Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin. Infect. Dis. 47(12), 1587–1592 (2008).
  • WHO. The poliovirus antivirals initiative. The Polio Pipeline 3, 4 (2009).
  • De Palma AM, Pürstinger G, Wimmer E et al. Potential use of antiviral agents in polio eradication. Emerging Infect. Dis. 14(4), 545–551 (2008).
  • Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication NRC. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. National Academies Press, DC, USA (2006).
  • Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Res. 79(3), 179–187 (2008).
  • Bablanian R, Eggers HJ, Tamm I. Inhibition of enterovirus cytopathic effects by 2-(alpha-hydroxybenzyl)-benzimidazole. J. Bacteriol. 91(3), 1289–1294 (1966).
  • Shimizu H, Agoh M, Agoh Y et al. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J. Virol. 74(9), 4146–4154 (2000).
  • Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69(7), 4189–4197 (1995).
  • Thys B, De Palma AM, Neyts J, Andries K, Vrijsen R, Rombaut B. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond. Antiviral Res. 78(3), 278–281 (2008).
  • Watson KG, Brown RN, Cameron R et al. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem. 46(15), 3181–3184 (2003).
  • Buontempo PJ, Cox S, Wright-Minogue J et al. SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob. Agents Chemother. 41(6), 1220–1225 (1997).
  • McKinlay MA, Steinberg BA. Oral efficacy of WIN 51711 in mice infected with human poliovirus. Antimicrob. Agents Chemother. 29(1), 30–32 (1986).
  • Binford SL, Maldonado F, Brothers MA et al. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 49(2), 619–626 (2005).
  • Patick AK, Brothers MA, Maldonado F et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 49(6), 2267–2275 (2005).
  • Geller R, Vignuzzi M, Andino R, Frydman J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21(2), 195–205 (2007).
  • Maynell LA, Kirkegaard K, Klymkowsky MW. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66(4), 1985–1994 (1992).
  • De Jesus NH. Epidemics to eradication: the modern history of poliomyelitis. Virol. J. 4, 70 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.